Drugs / PR104
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT00616213 | Feb → Sep 2008 | cancer of unknown primary site | Proacta, Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT00459836 | Feb 2007 → Oct 2009 | cancer of unknown primary site | Proacta, Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT01358227 | Dec 2006 → Dec 2009 | cancer of unknown primary site | Proacta, Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT00349167 | Dec 2005 → Jun 2007 | cancer of unknown primary site | Proacta, Incorporated | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01037556 | Jan 2010 → Dec 2012 | acute lymphoblastic leukemia, acute myeloid leukemia | Proacta, Incorporated | Unknown | No outcome recorded |
| Phase 1/2 | NCT00862082 | Mar 2009 → Jan 2010 | hepatocellular carcinoma | Proacta, Incorporated | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00862134 | Mar 2009 → Jan 2010 | non-small cell lung carcinoma | Proacta, Incorporated | Terminated | No outcome recorded |
| Phase 2 | NCT00544674 | Aug 2007 → Jul 2008 | lung cancer | Proacta, Incorporated | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PR104 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00544674 ↗ |
| Modality | Small molecule | “PR-104 is a "pre-prodrug" designed to be activated to a dinitrobenzamide nitrogen mustard cytotoxin” PMID 20012293 ↗ Dec 2009 |
| Route | Intravenous | “PR-104 IV over 60 minutes on day 1” NCT00349167 ↗ |